Morphine is widely used as an analgesic to treat moderate to severe pain, but chronic morphine use is associated with development of tolerance and dependence, which limits its analgesic efficacy. Our previous research has showed that nonanalgetic dose of a cannabinoid type 2 (CB2) receptor agonist reduced morphine tolerance in cancer pain. A previous study showed the colocalization of CB2 and transient receptor potential vanilloid 1 (TRPV1) in human and rat dorsal root ganglia (DRG) sensory neurons. Whether coadministration of a CB2 receptor agonist and morphine could reduce TRPV1 expression in morphine‑induced antinociception and tolerance in cancer pain is unclear. Therefore, we investigated the effects of coadministration of a CB2 receptor agonist AM1241 and morphine on TRPV1 expression and tolerance in cancer pain. Coadministration of AM1241 and morphine for 8 days significantly reduced morphine tolerance, as assessed by measuring paw withdrawal latency to a radiant heat stimulation, in Walker 256 tumor‑bearing rats. Repeated morphine treatment for a period of 8 days induced upregulation of the TRPV1 protein expression levels in the DRG in the tumor‑bearing rats, although no change in mRNA expression. Pretreatment with AM1241 reduced this morphine‑induced upregulation of TRPV1 and the effect was reversed by the CB2 receptor antagonist AM630. Our findings suggest that coadministration of a CB2 receptor agonist AM1241 and morphine reduced morphine tolerance possibly through regulation of TRPV1 protein expression in the DRG in cancer pain.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3892/mmr.2017.7479 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Negative Symptoms in Schizophrenia: An Update on Research Assessment and the Current and Upcoming Treatment Landscape.
CNS Drugs
January 2025
New York State Psychiatric Institute, 1051 Riverside Drive, New York, NY, 10032, USA.
Article Synopsis
- The negative symptoms of schizophrenia, like lack of emotion and motivation, are hard to treat and significantly impact daily functioning.
- This review highlights current research on treatment options for these symptoms, categorizing them into different types and evaluating various assessment scales.
- Although no treatments are conclusively proven as the best for these symptoms, some off-label and investigational medications show promise, including cariprazine and memantine, and further research is needed to explore new therapeutic possibilities.
The Future of Glucagon-Like Peptide-1 Receptor Agonists In Cardiovascular-Kidney-Metabolic Diseases.
Nephrol Dial Transplant
January 2025
Department of Nephrology, Hospital Universitario 12 de Octubre.
Novel oral adjuvant to enhance cytotoxic memory like NK cell responses in HIV vaccine platform.
NPJ Vaccines
January 2025
Department of Microbial Infection and Immunity, College of Medicine, The Ohio State University, Columbus, OH, USA.
Natural killer (NK) cell-driven effector mechanisms, such as antibody-dependent cell-mediated cytotoxicity, emerged as a secondary correlate of protection in the RV144 HIV vaccine clinical trial, the only vaccine thus far demonstrating some efficacy in human trials. Therefore, leveraging NK cells with enhanced cytotoxic effector responses may bolster vaccine-induced protection against HIV. Here, we investigated the effect of orally administering indole-3-carbinol (I3C), an aryl hydrocarbon receptor (AHR) agonist, as an adjuvant to an RV144-like vaccine platform in a mouse model.
View Article and Find Full Text PDFFXR-ApoC2 pathway activates UCP1-mediated thermogenesis by promoting the browning of white adipose tissues.
J Biol Chem
January 2025
Department of Science in Korean Medicine, Graduate School, Kyung Hee University, 02447, Seoul, Korea; Department of Pharmacology, College of Korean Medicine, Kyung Hee University, 02447, Seoul, Korea; Kyung Hee Institute of Convergence Korean Medicine, Kyung Hee University, 02447, Seoul, Korea. Electronic address:
FXR, encoded by Nh1r4, is a nuclear receptor crucial in regulating bile acid, lipid, and glucose metabolism. Prior research has indicated that activating FXR in the liver and small intestine may offer protection against obesity and metabolic diseases. This study demonstrates the essential role of the FXR-ApoC2 pathway in promoting the browning of white adipose tissue (WAT).
View Article and Find Full Text PDFN-terminal fragment shedding contributes to signaling of the full-length adhesion receptor ADGRL3.
J Biol Chem
January 2025
Department of Psychiatry, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA; Department of Molecular Pharmacology and Therapeutics, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA; Division of Molecular Therapeutics, New York State Psychiatric Institute, New York, NY, USA. Electronic address:
Most adhesion GPCRs undergo autoproteolytic cleavage during receptor biosynthesis, resulting in non-covalently bound N- and C-terminal fragments (NTF and CTF) that remain associated during receptor trafficking to the plasma membrane. While substantial evidence supports increased G protein signaling when just the CTF is expressed, there is an ongoing debate about whether NTF removal is required to initiate signaling in the context of the wild-type receptor. Here, we use adhesion GPCR latrophilin-3 (ADGRL3) as a model receptor to investigate tethered agonist-mediated activation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!